Pseudotargeted lipidomics analysis of scoparone on glycerophospholipid metabolism in non-alcoholic steatohepatitis mice by LC-MRM-MS
PeerJ · 21.05.2024 · 12 · e17380
DOI: 10.7717/peerj.17380 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, online erschienen am 21.05.2024. Verfasst von Qi Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Traditional Chinese Medicine, Hebei University, Baoding, Hebei, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Glycerophospholipids, Coumarins, Lipidomics. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hebei Province, Science and Technology Project of Hebei Education Department, Medical Science Foundation of Hebei University.
Abstract (Originalsprache)
As the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD), the progression of nonalcoholic steatohepatitis (NASH) is associated with disorders of glycerophospholipid metabolism. Scoparone is the major bioactive component in Artemisia capillaris which has been widely used to treat NASH in traditional Chinese medicine. However, the underlying mechanisms of scoparone against NASH are not yet fully understood, which hinders the development of effective therapeutic agents for NASH. Given the crucial role of glycerophospholipid metabolism in NASH progression, this study aimed to characterize the differential expression of glycerophospholipids that is responsible for scoparone’s pharmacological effects and assess its efficacy against NASH. Liquid chromatography-multiple reaction monitoring-mass spectrometry (LC-MRM-MS) was performed to get the concentrations of glycerophospholipids, clarify mechanisms of disease, and highlight insights into drug discovery. Additionally, pathologic findings also presented consistent changes in high-fat diet-induced NASH model, and after scoparone treatment, both the levels of glycerophospholipids and histopathology were similar to normal levels, indicating a beneficial effect during the observation time. Altogether, these results refined the insights on the mechanisms of scoparone against NASH and suggested a route to relieve NASH with glycerophospholipid metabolism. In addition, the current work demonstrated that a pseudotargeted lipidomic platform provided a novel insight into the potential mechanism of scoparone action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Traditional Chinese Medicine, Hebei University, Baoding, Hebei, China.
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
- Hebei Key Laboratory of Public Health Safety, School of Public HealthPublic Health, Hebei University, Baoding, Hebei, China.
- College of Basic Medical Science, Hebei University of Technology, Baoding, Hebei, China.
Förderung
- Natural Science Foundation of Hebei Province
- Science and Technology Project of Hebei Education Department
- Medical Science Foundation of Hebei University
- College Students’ Innovative Entrepreneurial Training Plan Program
Zitieren
APA
Song, Q., Zhao, Z., Liu, H., Zhang, J., Wang, Z., Zhang, Y., Ma, G., & Ge, S. (2024). Pseudotargeted lipidomics analysis of scoparone on glycerophospholipid metabolism in non-alcoholic steatohepatitis mice by LC-MRM-MS. PeerJ, 12, e17380. https://doi.org/10.7717/peerj.17380
Vancouver
Song Q, Zhao Z, Liu H, Zhang J, Wang Z, Zhang Y, et al. Pseudotargeted lipidomics analysis of scoparone on glycerophospholipid metabolism in non-alcoholic steatohepatitis mice by LC-MRM-MS. PeerJ. 2024;12:e17380. doi:10.7717/peerj.17380
BibTeX
@article{Song2024,
author = {Song, Qi and Zhao, Ziyi and Liu, Hu and Zhang, Jinling and Wang, Zhiqiang and Zhang, Yunqi and Ma, Guowei and Ge, Shaoqin},
title = {Pseudotargeted lipidomics analysis of scoparone on glycerophospholipid metabolism in non-alcoholic steatohepatitis mice by LC-MRM-MS},
journal = {PeerJ},
year = {2024},
volume = {12},
pages = {e17380},
doi = {10.7717/peerj.17380}
}
EUVIMED